Jonathan Jon Pilcher

Jon joined Neuren in 2013 as CFO and was appointed CEO in May 2020. He has played a central role in all aspects of Neuren s R&D, commercial and corporate activities. Before joining Neuren he was a member of the leadership team at Acrux (ASX: ACR) throughout a period that included Acruxs IPO and listing on the ASX, the development and FDA approval of three novel pharmaceutical products and a transforming licensing deal with Eli Lilly in 2010. He formerly spent seven years in a series of executive positions in the R&D and corporate functions of international pharmaceutical groups Medeva and Celltech, which are now part of UCB. Jon is a Chartered Accountant and holds a degree in Biotechnology from the University of Reading in the UK. He is a non executive director of BTC Health Limited (ASX: BTC).

Company and Roles

Company
Title
Tenure
Since
NEU
Neuren Pharmaceuticals Limited
  • Chief Executive Officer
  • Managing Director
10yrs, 6mthAug 2013

Holding

Company
Last Notice
Direct Shares
Indirect Shares
Options
Convertibles
NEU
Neuren Pharmaceuticals Limited
24/03/23N/A398,207N/AN/A

Transactions

Company
Date
Type
Amount
Price
Value
Notes
NEU
Neuren Pharmaceuticals Limited
08/10/21
Buy
7,317$2.050$15,000Participation in share purchase plan
NEU
Neuren Pharmaceuticals Limited
15/06/21
Buy
19,039$1.313$25,000On-market trade